Du är här


Bavarian Nordic A/S: Bavarian Nordic Initiates Phase 1 Clinical Trial of MVA-BN® in Respiratory Syncitial Virus (RSV)

COPENHAGEN, Denmark - August 18, 2015
- Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced the initiation
of a Phase 1 clinical study of its MVA-BN®RSV vaccine candidate against
respiratory syncytial virus (RSV), the first study to evaluate the vaccine
candidate in humans.

The study, which is being conducted in USA, will evaluate the safety,
tolerability and immunogenicity of a recombinant MVA-BN-based RSV vaccine in
63 healthy adults, ages 18-65. Subjects will be enrolled into three groups to
receive different doses of MVA-BN RSV. One group will enroll subjects of
50-65 years of age who will receive a higher dose of MVA-BN RSV in order to
evaluate the immune responses in an elderly population, which is a key target
for the vaccine. Volunteers in each group will be randomized to receive two
vaccinations of MVA-BN RSV vaccine or placebo. More information on the trial
can be found athttps://clinicaltrials.gov/ct2/show/NCT02419391.

Paul Chaplin, President&Chief Executive Officer of Bavarian Nordic, said: "The
addition of RSV to our clinical pipeline significantly expands the commercial
potential of our MVA-BN vaccine platform technology. RSV is an exciting
opportunity as it represents an area of high unmet medical need with no
approved vaccine available. Based on the broad protection seen in our
preclinical data, we believe that MVA-BN has the potential to address this
opportunity. Once data from this initial study are available, we plan to
aggressively pursue the development of this promising vaccine candidate in
all potential risk populations, including elderly and young children."


Rolf Sass Sørensen
Vice President Investor Relations (EU)
Tel: +45 61 77 47 43

Seth Lewis
Vice President Investor Relations (US)
Tel: +1 978 341 5271

About RSV

RSV is the most common cause of lower respiratory tract infection in infants
and children worldwide, resulting in a high number of hospitalizations. By 2
years of age virtually all infants have had an RSV infection. In addition,
RSV causes serious disease in elderly and immune compromised individuals, and
results in a comparable number of deaths in the elderly population as
influenza. Currently, there is no approved RSV vaccine available for any of
these populations. It is estimated that more than 64 million people are
infected globally each year, thus representing a blockbuster market
opportunity for a safe and effective vaccine.


Bavarian Nordic's recombinant MVA-BN-based RSV vaccine candidate has been
shown to induce a balanced humoral and cellular immune response against both
RSV subtypes in preclinical models. Furthermore, the candidate has been shown
to be highly efficacious in preclinical models, including in studies
sponsored by the NIH.

About MVA-BN®

MVA-BN (Modified Vaccinia Ankara - Bavarian Nordic) is a proprietary and
patented vaccine platform technology of Bavarian Nordic, originally developed
through a successful public-private partnership with the U.S. Government.
MVA-BN is a robust and adaptable platform suitable for addressing a wide
variety of infectious diseases.

In addition to developing MVA-BN as a safer smallpox vaccine (approved in the
EU and Canada) essential to protecting the immune-compromised population, and
through a partnership with Janssen as an Ebola vaccine, Bavarian Nordic has
conducted more than a dozen preclinical and clinical studies of recombinant
MVA-BN-based vaccines. More than 7,600 individuals, nearly 1,000 of whom are
immunocompromised, have been vaccinated with MVA-BN-based vaccines, showing
the platform displays high immunogenicity and a favorable safety profile.

About Bavarian Nordic

Bavarian Nordic is a biopharmaceutical company focused on the development and
manufacturing of cancer immunotherapies and vaccines for infectious diseases.
Through a long-standing collaboration with the U.S. Government, Bavarian
Nordic has developed a portfolio of biological countermeasures, including the
non-replicating smallpox vaccine, IMVAMUNE®, which is stockpiled for
emergency use by the U.S. and other governments. The vaccine is approved in
the EU (under the trade name IMVANEX®) and in Canada. Bavarian Nordic and its
partner Janssen are pioneering the development of an Ebola vaccine, which has
been fast-tracked by authorities in response to the current situation in West
Africa. Additionally, in collaboration with the National Cancer Institute,
Bavarian Nordic has developed a portfolio of active cancer immunotherapies
based on its versatile pox-virus based technologies, including PROSTVAC®,
which is currently in Phase 3 clinical development for the treatment of
advanced prostate cancer. The company has partnered with Bristol-Myers Squibb
for the potential commercialization of PROSTVAC. For more information
visitwww.bavarian-nordic.comor follow us on Twitter@bavariannordic.

Forward-looking statements

This announcement includes forward-looking statements that involve risks,
uncertainties and other factors, many of which are outside of our control
that could cause actual results to differ materially from the results
discussed in the forward-looking statements. Forward-looking statements
include statements concerning our plans, objectives, goals, future events,
performance and/or other information that is not historical information. We
undertake no obligation to publicly update or revise forward-looking
statements to reflect subsequent events or circumstances after the date made,
except as required by law.



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bavarian Nordic A/S via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.